Featured Publications
Welcome to the Real World Understanding the Many Faces of Osimertinib-Related Pneumonitis
Possick J. Welcome to the Real World Understanding the Many Faces of Osimertinib-Related Pneumonitis. CHEST Journal 2022, 162: 965-967. PMID: 36344125, DOI: 10.1016/j.chest.2022.06.020.Commentaries, Editorials and LettersPulmonary Complications of Immunotherapy
Bade BC, Possick JD. Pulmonary Complications of Immunotherapy. Clinics In Chest Medicine 2020, 41: 295-305. PMID: 32402364, DOI: 10.1016/j.ccm.2020.02.012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLung cancerImmune checkpoint inhibitor therapyImmune-related adverse eventsTreatment-limiting complicationsCheckpoint inhibitor therapyFurther prospective investigationMetastatic lung cancerFavorable safety profileTreatment of patientsPulmonary complicationsAdverse eventsClinical vigilanceInhibitor therapySignificant morbiditySafety profileProspective InvestigationCurrent guidelinesMortality riskImmunotherapyComplicationsPatientsCancerPneumonitisMorbidityChemotherapyKnowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement
Sears CR, Peikert T, Possick JD, Naidoo J, Nishino M, Patel SP, Camus P, Gaga M, Garon EB, Gould MK, Limper AH, Montgrain PR, Travis WD, Rivera MP. Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement. American Journal Of Respiratory And Critical Care Medicine 2019, 200: e31-e43. PMID: 31518182, PMCID: PMC6775885, DOI: 10.1164/rccm.201906-1202st.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmune checkpoint inhibitorsICI-pneumonitisCheckpoint inhibitorsOfficial American Thoracic Society Research StatementUse of ICIsLife-threatening pneumonitisUnique adverse eventsBiological mechanismsAdverse eventsRadiologic featuresRadiologic presentationCancer careBiologic mechanismsResearch prioritiesBasic biological mechanismsMultidisciplinary groupPneumonitisClinical researchersDiagnosisInhibitorsPrecipitous increaseTherapyAvailable dataCare- Tanoue LT, McArdle JR, Possick JD. Pulmonary Toxicity Associated with Chemotherapeutic Agents. In Grippi M, Elias J, Fishman J, et al. Fishman’s Pulmonary Diseases and Disorders, 5th edition. New York: McGraw-Hill, 2015Chapters
Pulmonary Disease in Non-Pulmonary Malignancy
Cheng GS, Possick JD. Pulmonary Disease in Non-Pulmonary Malignancy. Clinics In Chest Medicine 2017, 38: xiii-xiv. PMID: 28477646, DOI: 10.1016/j.ccm.2017.03.001.ChaptersPulmonary Toxicities from Checkpoint Immunotherapy for Malignancy
Possick JD. Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy. Clinics In Chest Medicine 2017, 38: 223-232. PMID: 28477635, DOI: 10.1016/j.ccm.2016.12.012.ChaptersPulmonary Complications of Lung Cancer Treatment
McAvoy K, Possick J. Pulmonary Complications of Lung Cancer Treatment. Respiratory Medicine 2023, 229-254. DOI: 10.1007/978-3-031-38412-7_11.ChaptersPulmonary complicationsTreatment-related risk factorsNonspecific respiratory symptomsLife-saving therapyLung cancer treatmentLung cancer therapyUnderstanding of patientsRespiratory symptomsRadiographic findingsAttendant complicationsDiagnostic challengeRisk factorsTreatment paradigmRadiation therapyTraditional chemotherapyComplicationsAccurate diagnosisAreas of uncertaintyCancer treatmentTherapyCancer therapyDisease responsePatientsImmunotherapyChemotherapyA Novel Ambulatory Curriculum for Pulmonary and Critical Care Fellows Utilizing Adult Learning Theory and Multi-disciplinary Teachers
Mcavoy K, Honiden S, Possick J. A Novel Ambulatory Curriculum for Pulmonary and Critical Care Fellows Utilizing Adult Learning Theory and Multi-disciplinary Teachers. 2023, a4303-a4303. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4303.Peer-Reviewed Original ResearchA Clinic Blueprint for Post-Coronavirus Disease 2019 RECOVERY Learning From the Past, Looking to the Future
Lutchmansingh DD, Knauert MP, Antin-Ozerkis DE, Chupp G, Cohn L, Dela Cruz CS, Ferrante LE, Herzog EL, Koff J, Rochester CL, Ryu C, Singh I, Tickoo M, Winks V, Gulati M, Possick JD. A Clinic Blueprint for Post-Coronavirus Disease 2019 RECOVERY Learning From the Past, Looking to the Future. CHEST Journal 2020, 159: 949-958. PMID: 33159907, PMCID: PMC7641526, DOI: 10.1016/j.chest.2020.10.067.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute diseaseRespiratory syndromeSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Post-intensive care syndromePotential long-term complicationsCOVID-19Respiratory syndrome coronavirus 2Middle East respiratory syndromeSevere acute respiratory syndromeCoronavirus disease 2019 (COVID-19) casesPersistent respiratory symptomsLong-term complicationsCOVID-19 survivorsSyndrome coronavirus 2Acute respiratory syndromeCOVID-19 outcomesChronic complicationsPersistent symptomsRespiratory symptomsCoronavirus 2Lung diseaseNonhospitalized individualsClinical programsComplicationsCardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing
Medeiros BC, Possick J, Fradley M. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. Blood Reviews 2018, 32: 289-299. PMID: 29454474, DOI: 10.1016/j.blre.2018.01.004.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic myeloid leukemiaTyrosine kinase inhibitorsComorbid risk factorsMyeloid leukemiaTyrosine kinase inhibitor therapyPatients' disease profilesTreatment-limiting complicationsAdverse event profileKinase inhibitor therapyTKI selectionInhibitor therapyPrompt managementEvent profileTKI agentsCML treatmentPulmonary disordersPulmonary toxicityRisk factorsToxicity profileMyeloproliferative neoplasmsSymptoms of toxicityDisease profileMetabolic toxicityKinase inhibitorsAppropriate agentChapter 15 Diagnosis and Management of Treatment-Related Pulmonary Complications
Possick J. Chapter 15 Diagnosis and Management of Treatment-Related Pulmonary Complications. 2018, 221-241. DOI: 10.1016/b978-0-323-48565-4.00015-1.ChaptersLung cancerPulmonary complicationsPulmonary toxicityGenotype-directed targeted therapyPossible treatment-related complicationsSecond primary lung cancerEarly-stage lung cancerRadiation-induced pulmonary toxicityAppropriate clinical presentationNew pulmonary symptomsPotential treatment complicationsTreatment-related complicationsTreatment-related toxicityPrimary lung cancerDiagnosis of exclusionPrior surgical resectionManagement of treatmentManagement of individualsGold standard testABSTRACT ComplicationsPulmonary comorbiditiesPulmonary reserveAdvanced diseasePulmonary symptomsSystemic chemotherapy
2024
Impact of Ambulatory Blocks on Pulmonary Critical Care Fellow Outpatient Training Experience
McAvoy K, Gielissen K, Possick J, Honiden S. Impact of Ambulatory Blocks on Pulmonary Critical Care Fellow Outpatient Training Experience. ATS Scholar 2024, 5: 286-301. PMID: 39055327, PMCID: PMC11270235, DOI: 10.34197/ats-scholar.2023-0130oc.Peer-Reviewed Original Research
2023
Distinguishing features of long COVID identified through immune profiling
Klein J, Wood J, Jaycox J, Dhodapkar R, Lu P, Gehlhausen J, Tabachnikova A, Greene K, Tabacof L, Malik A, Silva Monteiro V, Silva J, Kamath K, Zhang M, Dhal A, Ott I, Valle G, Peña-Hernández M, Mao T, Bhattacharjee B, Takahashi T, Lucas C, Song E, McCarthy D, Breyman E, Tosto-Mancuso J, Dai Y, Perotti E, Akduman K, Tzeng T, Xu L, Geraghty A, Monje M, Yildirim I, Shon J, Medzhitov R, Lutchmansingh D, Possick J, Kaminski N, Omer S, Krumholz H, Guan L, Dela Cruz C, van Dijk D, Ring A, Putrino D, Iwasaki A. Distinguishing features of long COVID identified through immune profiling. Nature 2023, 623: 139-148. PMID: 37748514, PMCID: PMC10620090, DOI: 10.1038/s41586-023-06651-y.Peer-Reviewed Original ResearchConceptsLong COVIDSARS-CoV-2Infection syndromeExaggerated humoral responseSoluble immune mediatorsEpstein-Barr virusPost-exertional malaiseCross-sectional studyHigher antibody responseImmune mediatorsImmune phenotypingImmune profilingHumoral responseAntibody responseLymphocyte populationsCOVID statusUnbiased machineCortisol levelsLC statusRelevant biomarkersViral pathogensSyndromeCOVIDFuture studiesBiological featuresDifferences in Mortality Among Patients With Asthma and COPD Hospitalized With COVID-19
Liu Y, Rajeevan H, Simonov M, Lee S, Wilson F, Desir G, Vinetz J, Yan X, Wang Z, Clark B, Possick J, Price C, Lutchmansingh D, Ortega H, Zaeh S, Gomez J, Cohn L, Gautam S, Chupp G. Differences in Mortality Among Patients With Asthma and COPD Hospitalized With COVID-19. The Journal Of Allergy And Clinical Immunology In Practice 2023, 11: 3383-3390.e3. PMID: 37454926, PMCID: PMC10787810, DOI: 10.1016/j.jaip.2023.07.006.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseType 2 inflammationCOVID-19 severitySOFA scoreAirway diseaseNoneosinophilic asthmaSequential Organ Failure Assessment scoreOrgan Failure Assessment scoreSevere coronavirus disease 2019Higher SOFA scoreMedian SOFA scoreRetrospective cohort studyObstructive pulmonary diseaseOdds of mortalityLower SOFA scoresCells/μLCOVID-19 outcomesCoronavirus disease 2019Logistic regression analysisCOVID-19Clinical confoundersAsthma patientsCohort studyImmunological factorsClinical featuresMortality Differences Among Patients With Airway Disease Hospitalized With COVID-19
Liu Y, Rajeevan H, Simonov M, Wilson F, Desir G, Vinetz J, Yan X, Wang Z, Clark B, Possick J, Price C, Lutchmansingh D, Gomez J, Cohn L, Gautam S, Chupp G. Mortality Differences Among Patients With Airway Disease Hospitalized With COVID-19. 2023, a6297-a6297. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6297.Peer-Reviewed Original ResearchProteomic profiling demonstrates inflammatory and endotheliopathy signatures associated with impaired cardiopulmonary exercise hemodynamic profile in Post Acute Sequelae of SARS‐CoV‐2 infection (PASC) syndrome
Singh I, Leitner B, Wang Y, Zhang H, Joseph P, Lutchmansingh D, Gulati M, Possick J, Damsky W, Hwa J, Heerdt P, Chun H. Proteomic profiling demonstrates inflammatory and endotheliopathy signatures associated with impaired cardiopulmonary exercise hemodynamic profile in Post Acute Sequelae of SARS‐CoV‐2 infection (PASC) syndrome. Pulmonary Circulation 2023, 13: e12220. PMID: 37091121, PMCID: PMC10113513, DOI: 10.1002/pul2.12220.Peer-Reviewed Original ResearchInvasive cardiopulmonary exercise testPASC patientsPost-acute sequelaeAcute sequelaeInfection syndromeUnexplained exertional intoleranceCardiopulmonary exercise testSystemic oxygen deliveryPersistent inflammatory stateVenous blood plasmaExertional intolerancePeak exerciseEndothelial dysfunctionHemodynamic profileInflammatory stateExercise testFibrotic processPathophysiological hallmarkAberrant protein expressionExpression of proteinsOxygen deliveryOxygen extractionProteomic profilingPatientsPhysiologic responses“Long Haulers”
Lutchmansingh D, Sevilla J, Possick J, Gulati M. “Long Haulers”. Seminars In Respiratory And Critical Care Medicine 2023, 44: 130-142. PMID: 36646091, DOI: 10.1055/s-0042-1759568.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPost-COVID conditionsAcute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionSARS-CoV-2 infectionChronic COVID-19Long-haul COVIDOngoing interventional trialsLong-term morbidityCoronavirus disease 2019Multiple organ systemsInterventional trialsLong COVIDTreatment algorithmNeuropsychiatric sequelaePostacute sequelaeRisk factorsObservational studyDisease 2019Long-term effectsSurvivors' qualityClinical protocolsLong haulersOrgan systems
2022
AMBULATORY BLOCK STRUCTURE TO IMPROVE FELLOW OUTPATIENT PULMONARY MEDICINE EXPOSURE AND EDUCATION
MCAVOY K, POSSICK J, HONIDEN S. AMBULATORY BLOCK STRUCTURE TO IMPROVE FELLOW OUTPATIENT PULMONARY MEDICINE EXPOSURE AND EDUCATION. CHEST Journal 2022, 162: a2599. DOI: 10.1016/j.chest.2022.08.2124.Peer-Reviewed Original Research
2021
Persistent Exertional Intolerance After COVID-19 Insights From Invasive Cardiopulmonary Exercise Testing
Singh I, Joseph P, Heerdt PM, Cullinan M, Lutchmansingh DD, Gulati M, Possick JD, Systrom DM, Waxman AB. Persistent Exertional Intolerance After COVID-19 Insights From Invasive Cardiopulmonary Exercise Testing. CHEST Journal 2021, 161: 54-63. PMID: 34389297, PMCID: PMC8354807, DOI: 10.1016/j.chest.2021.08.010.Peer-Reviewed Original ResearchConceptsInvasive cardiopulmonary exercise testingCardiopulmonary exercise testingCardiopulmonary diseaseExercise testingControl participantsPeak VOExertional limitationCOVID-19Greater ventilatory inefficiencyPeak cardiac indexSex-matched control participantsCohort of patientsSystemic oxygen extractionDead space ventilationOnly mild symptomsExertional intoleranceCardiac indexPulmonary hemodynamicsAcute infectionVentilatory inefficiencyExercise intolerancePathophysiologic mechanismsMild symptomsHyperventilatory responseOxygen extraction
2019
Teaching Communication Skills
Possick J, Akgün K. Teaching Communication Skills. Respiratory Medicine 2019, 195-212. DOI: 10.1007/978-3-030-10680-5_11.Chapters